Clinical Trial Update: Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

View source ↗

Summary

Results have been posted for Pfizer's infliximab biosimilar trial evaluating its use in Crohn's disease and ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• INFLECTRA (infliximab-dyyb)

Snippet

Sponsor: Pfizer | Conditions: Crohn's Disease, Ulcerative Colitis | Status: COMPLETED | Results posted: 2025-03-21